[Anti-tumor vaccination].
Five year survival rates are presented for 32 primary operated breast cancer patients who were postoperatively treated with an optimal dose of autologous NDV-modified tumor vaccine. Their overall survival and their recurrent-free survival was significantly better than that of 31 comparable breast cancer patients treated simultaneously with a suboptimal dose of the same type of vaccine. The concept, development and mechanism of action of this vaccine are als commented on.
Schirrmacher
V
V
Deutsches Krebsforschungszentrum, Heidelberg.
D000818:Animals; D001943:Breast Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D019496:Cancer Vaccines / Q000276:immunology; D017322:Clinical Trials, Phase II as Topic; D015331:Cohort Studies; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D016233:Immunotherapy, Active; D051379:Mice; D009522:Newcastle disease virus / Q000276:immunology*; D011182:Postoperative Care; D012307:Risk Factors; D013997:Time Factors
D019496:Cancer Vaccines